Skip to content

ENDOCYTE INC: 10-Q filed 2012-11-13

What ENDOCYTE INC reported in its quarterly report filed 2012-11-13 (fiscal Q3 2012): 29 published measures, 76 facts as tagged in accession 0001144204-12-061382.

This filing

Form
10-Q (quarterly report)
Filed
2012-11-13
Fiscal period
fiscal Q3 2012
Accession
0001144204-12-061382 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENDOCYTE INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-30215,821,469USD
At 2011-12-31131,675,104USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-09-30116,203,812USD
At 2011-12-3118,303,181USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-3099,617,657USD
At 2011-12-31113,371,923USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-3036,728,677USD
At 2011-12-3161,352,483USD
At 2011-09-3066,640,995USD
At 2010-12-3116,872,783USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,239,366USD92
2012-01-01 to 2012-09-30-16,443,164USD274
2011-07-01 to 2011-09-30-12,069,907USD92
2011-01-01 to 2011-09-30-29,777,602USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-09-3091,917,129USD274
2011-01-01 to 2011-09-30-23,915,701USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-09-301,626,280USD274
2011-01-01 to 2011-09-30198,810USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-13,176,579USD274
2011-01-01 to 2011-09-30146,287,858USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-103,366,980USD274
2011-01-01 to 2011-09-30-72,602,837USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-09-30-155,043,684USD
At 2011-12-31-138,600,520USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-09-302,531,863USD
At 2011-12-311,107,851USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-09-302,248,354USD274
2011-01-01 to 2011-09-301,345,609USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,331,073USD92
2012-01-01 to 2012-09-30-15,029,702USD274
2011-07-01 to 2011-09-30-11,638,873USD92
2011-01-01 to 2011-09-30-28,213,510USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-30197,380,486USD
At 2011-12-31129,756,024USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-07-01 to 2012-09-30891USD92
2012-01-01 to 2012-09-30628,215USD274
2011-07-01 to 2011-09-30448,762USD92
2011-01-01 to 2011-09-301,637,022USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-09-3055,501,139USD
At 2011-12-315,470,002USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-09-302,080,682USD
At 2011-12-312,125,500USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-07-01 to 2012-09-3013,745,757USD92
2012-01-01 to 2012-09-3035,257,351USD274
2011-07-01 to 2011-09-3011,638,873USD92
2011-01-01 to 2011-09-3028,213,510USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-07-01 to 2012-09-309,930,766USD92
2012-01-01 to 2012-09-3025,153,659USD274
2011-07-01 to 2011-09-308,915,577USD92
2011-01-01 to 2011-09-3021,075,853USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-09-3035,906,490shares
At 2011-12-3135,784,485shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2012-09-3066,684USD
At 2011-12-31-6,264USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2012-09-30631,757USD
At 2011-12-31811,229USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-09-301,346,070USD
At 2011-12-311,540,749USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,122,967USD92
2012-01-01 to 2012-09-30-16,370,216USD274
2011-07-01 to 2011-09-30-12,085,831USD92
2011-01-01 to 2011-09-30-29,763,750USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-303,814,991USD92
2012-01-01 to 2012-09-3010,103,692USD274
2011-07-01 to 2011-09-302,723,296USD92
2011-01-01 to 2011-09-307,137,657USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-01-01 to 2012-09-30244,004USD274
2011-01-01 to 2011-09-30200,326USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-3,861USD92
2012-01-01 to 2012-09-30-922,744USD274
2011-07-01 to 2011-09-30-17,646USD92
2011-01-01 to 2011-09-30-18,308USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-07-01 to 2011-09-3066,700,000USD92
2011-01-01 to 2011-03-3178,200,000USD90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-489,281USD274
2011-01-01 to 2011-09-301,302,055USD273

Inspect the source

Entity
ENDOCYTE INC / CIK 0001235007
Captured
SEC response SHA-256
fa7da76c073b3895ba6769212bf598e872bbf5f159d8c19a8ae123614d925339

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001235007.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))